Plain-English translation of NCT07383103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Septic shock is a life-threatening condition where a severe infection causes the body's organs to fail. This trial is testing whether giving patients hydrocortisone and fludrocortisone together — two medications that help the body manage stress — works better and safer than current standard treatment alone. These medications are given by IV infusion and by mouth for up to a week in the intensive care unit.
Patients with septic shock often have deficiencies in natural stress hormones, and current guidelines only recommend one of these medications. Researchers want to know if using both medications together can help more patients survive and recover faster, and whether combining them is safe.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the two medications together (hydrocortisone through an IV and fludrocortisone by mouth) or standard care alone. You will receive the treatment in the intensive care unit for up to 7 days or until you are discharged, whichever comes first. Your medical team will monitor your condition closely throughout.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
Northern Jiangsu People's Hospital
Enrollment target
~336 participants
Started
March 2026
Primary completion
December 2028
Age range
18 Years – 90 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qingquan Lyu, Master
Northern Jiangsu People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.